Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus

Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): Safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy

(2017) L. Wood et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

(2009) Robert J. Amato et al.   CANCER

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

(2008) J. Bellmunt et al.   ANNALS OF ONCOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

(2008) Anne O'Donnell et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function

(2008) Paolo De Simone et al.   TRANSPLANT INTERNATIONAL

Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell Carcinoma

(2007) Naeem Bhojani et al.   EUROPEAN UROLOGY

Molecular pathophysiology and physical chemistry of cholesterol gallstones

(2007) Helen et al.   Frontiers in Bioscience-Landmark